Browsing Barts Cancer Institute by Subject "pancreatic cancer"
Now showing items 1-12 of 12
-
AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting.
(2019-07-02)Anterior gradient 2 (AGR2), a protein disulfide isomerase, shows two subcellular localizations: intracellular (iAGR2) and extracellular (eAGR2). In healthy cells that express AGR2, the predominant form is iAGR2, which ... -
Chemotherapy Assessment in Advanced Multicellular 3D Models of Pancreatic Cancer: Unravelling the Importance of Spatiotemporal Mimicry of the Tumor Microenvironment.
(2024-02-07)Pancreatic ductal adenocarcinoma (PDAC) is a challenge for global health with very low survival rate and high therapeutic resistance. Hence, advanced preclinical models for treatment screening are of paramount importance. ... -
Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.
(2019)B cells are salient features of pancreatic ductal adenocarcinoma (PDAC) tumors, yet their role in this disease remains controversial. Murine studies have indicated a protumoral role for B cells, whereas clinical data show ... -
A faecal microbiota signature with high specificity for pancreatic cancer.
(2022-07)BACKGROUND: Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. OBJECTIVE: To explore the faecal and salivary microbiota as potential diagnostic biomarkers. ... -
Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling.
(FEBS Press and John Wiley & Sons Ltd., 2019-01-28)Perineural invasion (PNI) is a common and characteristic feature of pancreatic ductal adenocarcinoma (PDAC) that is associated with poor prognosis, tumor recurrence, and generation of pain. However, the molecular alterations ... -
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
(2018-08-18)OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a disease of unmet medical need. While immunotherapy with chimeric antigen receptor T (CAR-T) cells has shown much promise in haematological malignancies, their efficacy ... -
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
(Oxford University Press, 2017-04-05)Background Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, many patients suffer or have suffered from other diseases. Identifying disease patterns associated with PDAC risk may ...